Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2012 Sep 10;14(11):1379–1392. doi: 10.1093/neuonc/nos158

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2012. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

PMC Copyright notice

Fig. 4. — Antiangiogenic agents modulate CD11b⁺/F4/80⁺/Gr1⁻ myeloid cell recruitment to tumors. (A) Representative flow cytometry analyses from tumor at 4 and 6 weeks in each group. (B) Upper panel, bar graph demonstrating the average percentage of CD11b+/F4/80+/Gr1- myeloid cells at each time point for the 4 treatment groups. Lower panel, bar graph showing average percentage of CD11b+/Gr1- cells expressing VEGFR1+. (C) Top, representative photomicrographs of CD68 macrophage staining at the corresponding time points. Bottom, bar graph of fractional area of CD68 staining. *P < .05 compared with controls; #P < .05 compared with sunitinib treated animals. (D) Positive correlation between number of CD11b+/F4/80+/Gr1- macrophages using flow cytometry and fractional area of CA9 staining.

Fig. 4. — Antiangiogenic agents modulate CD11b⁺/F4/80⁺/Gr1⁻ myeloid cell recruitment to tumors. (A) Representative flow cytometry analyses from tumor at 4 and 6 weeks in each group. (B) Upper panel, bar graph demonstrating the average percentage of CD11b+/F4/80+/Gr1- myeloid cells at each time point for the 4 treatment groups. Lower panel, bar graph showing average percentage of CD11b+/Gr1- cells expressing VEGFR1+. (C) Top, representative photomicrographs of CD68 macrophage staining at the corresponding time points. Bottom, bar graph of fractional area of CD68 staining. *P < .05 compared with controls; #P < .05 compared with sunitinib treated animals. (D) Positive correlation between number of CD11b+/F4/80+/Gr1- macrophages using flow cytometry and fractional area of CA9 staining.